Protagonist Therapeutics. has been granted a patent for pharmaceutical compositions that include chemokine or G-protein coupled receptors, aimed at treating immune disorders. The patent also covers specific CKRD peptides that bind to various cytokines and exhibit anti-inflammatory properties. GlobalData’s report on Protagonist Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Protagonist Therapeutics, Cyclosporin derivatives was a key innovation area identified from patents. Protagonist Therapeutics's grant share as of July 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical compositions for treating immune system disorders
The granted patent US12072338B2 outlines a novel CKRD peptide with specific amino acid sequences designed to bind to various cytokines, including MIG, I-309, Eotaxin, and SDF1 variants, among others. The claims detail two primary peptide forms, one consisting of the amino acid sequence WVFGSGLCK (SEQ ID NO: 16) and another with a modified sequence WVFGHGMCK (SEQ ID NO: 2). Notably, the patent specifies that the CKRD peptide can have substitutions at amino acid positions 5, 6, and 7, which can enhance its binding affinity to these cytokines, contributing to its anti-inflammatory properties. The peptide is also characterized by its ability to bind with a dissociation constant of less than 1 mM to various chemokines, including Fractalkine and Lymphotactin, as well as dual-function chemokines like SDF1-a and MIP3-a.
Additionally, the patent claims the formulation of a pharmaceutical composition that includes the CKRD peptide along with a pharmaceutically acceptable carrier. This composition is proposed for therapeutic applications, particularly in the treatment of rheumatoid arthritis, by administering the CKRD peptide to patients in need. The claims emphasize the peptide's potential utility in modulating inflammatory responses, thereby offering a targeted approach to managing conditions associated with excessive cytokine activity.
To know more about GlobalData’s detailed insights on Protagonist Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
